MeiraGTx, LLC
Clinical trials sponsored by MeiraGTx, LLC, explained in plain language.
A gene therapy company, subsidiary of MeiraGTx Holdings.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a single gene therapy dose restore saliva flow years after radiation? Results expected Mar 2027 (estimated)
- Gene therapy could restore saliva flow in dry mouth sufferers Results expected Jun 2027 (estimated)
-
New gene therapy aims to restore saliva in cancer survivors
Disease control CompletedThis study tests a gene therapy designed to help people with dry mouth after radiation for head and neck cancer. The treatment delivers a gene into one saliva gland to help it produce more saliva. The trial includes 17 adults and focuses on safety, with follow-up over three years…
Phase 1 • Sponsor: MeiraGTx, LLC • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Brain gene therapy tested for Parkinson's – early results in
Disease control CompletedThis early-stage trial tested a gene therapy for Parkinson's disease. The treatment involved delivering a gene called GAD into a brain region that controls movement. Only 14 people took part, and the main goal was to check safety, not whether it works. The study is now complete.
Phase 1/2 • Sponsor: MeiraGTx, LLC • Aim: Disease control
Last updated Jun 26, 2026 14:07 UTC